SPONSOR: Sen. Poore & Rep. Minor-Brown Sens. Gay, Hoffner, Mantzavinos, Sokola, Wilson DELAWARE STATE SENATE 152nd GENERAL ASSEMBLY SENATE CONCURRENT RESOLUTION NO. 157 DESIGNATING MAY 5 11, 2024, AS TARDIVE DYSKINESIA AWARENESS WEEK IN DELAWARE.
SPONSOR: Sen. Poore & Rep. Minor-Brown Sens. Gay, Hoffner, Mantzavinos, Sokola, Wilson
SPONSOR: Sen. Poore & Rep. Minor-Brown
Sens. Gay, Hoffner, Mantzavinos, Sokola, Wilson
SPONSOR:
Sen. Poore & Rep. Minor-Brown
Sens. Gay, Hoffner, Mantzavinos, Sokola, Wilson
DELAWARE STATE SENATE
152nd GENERAL ASSEMBLY
SENATE CONCURRENT RESOLUTION NO. 157
DESIGNATING MAY 5 11, 2024, AS TARDIVE DYSKINESIA AWARENESS WEEK IN DELAWARE.
WHEREAS, many people living with serious mental illnesses (for example, bipolar disorder, major depressive disorder, schizophrenia, and schizoaffective disorder) or gastrointestinal disorders (for example, gastroparesis, upset stomach, nausea, and vomiting) may be treated with medications that work as dopamine receptor blocking agents, including antipsychotics and antiemetics; and WHEREAS, while ongoing treatment with these medications can be necessary, prolonged use is associated with tardive dyskinesia (TD), an involuntary movement disorder that is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, limbs, and fingers or toes; and WHEREAS, even mild symptoms of TD can impact people physically, socially, and emotionally; and WHEREAS, it is estimated that TD affects approximately 600,000 people in the United States, and approximately 65 percent of people with TD have not been diagnosed, making it important to raise awareness about the symptoms; and WHEREAS, it is important that people taking these medications be monitored for TD by a healthcare provider, and regular screening for TD is recommended by the American Psychiatric Association; and WHEREAS, clinical research has led to approval of treatments for adults with TD by the U.S. Food and Drug Administration, and recognition and treatment of TD can make a positive impact in the lives of many people experiencing psychotic and mood disorders and gastrointestinal disorders ; and WHEREAS, the Department of Health and Social Services can raise awareness of TD among the public and medical community. NOW, THEREFORE: BE IT RESOLVED by the Senate of the 152nd General Assembly of the State of Delaware, the House of Representatives concurring therein, that the week of May 5-11, 2024, is designated as Tardive Dyskinesia Awareness Week in the State of Delaware. BE IT FURTHER RESOLVED that this General Assembly encourages Delawareans who are experiencing uncontrollable, abnormal, and repetitive movements to consult their healthcare provider regarding their symptoms. BE IT FURTHER RESOLVED that this General Assembly encourages all Delawareans to become better informed about Tardive Dyskinesia.
WHEREAS, many people living with serious mental illnesses (for example, bipolar disorder, major depressive disorder, schizophrenia, and schizoaffective disorder) or gastrointestinal disorders (for example, gastroparesis, upset stomach, nausea, and vomiting) may be treated with medications that work as dopamine receptor blocking agents, including antipsychotics and antiemetics; and
WHEREAS, while ongoing treatment with these medications can be necessary, prolonged use is associated with tardive dyskinesia (TD), an involuntary movement disorder that is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, limbs, and fingers or toes; and
WHEREAS, even mild symptoms of TD can impact people physically, socially, and emotionally; and
WHEREAS, it is estimated that TD affects approximately 600,000 people in the United States, and approximately 65 percent of people with TD have not been diagnosed, making it important to raise awareness about the symptoms; and
WHEREAS, it is important that people taking these medications be monitored for TD by a healthcare provider, and regular screening for TD is recommended by the American Psychiatric Association; and
WHEREAS, clinical research has led to approval of treatments for adults with TD by the U.S. Food and Drug Administration, and recognition and treatment of TD can make a positive impact in the lives of many people experiencing psychotic and mood disorders and gastrointestinal disorders ; and
WHEREAS, the Department of Health and Social Services can raise awareness of TD among the public and medical community.
NOW, THEREFORE:
BE IT RESOLVED by the Senate of the 152nd General Assembly of the State of Delaware, the House of Representatives concurring therein, that the week of May 5-11, 2024, is designated as Tardive Dyskinesia Awareness Week in the State of Delaware.
BE IT FURTHER RESOLVED that this General Assembly encourages Delawareans who are experiencing uncontrollable, abnormal, and repetitive movements to consult their healthcare provider regarding their symptoms.
BE IT FURTHER RESOLVED that this General Assembly encourages all Delawareans to become better informed about Tardive Dyskinesia.
SYNOPSIS This resolution designates May 5-11, 2024, as Tardive Dyskinesia Awareness Week and encourages anyone experiencing uncontrollable, abnormal, and repetitive movements to consult their healthcare provider regarding their symptoms. Author: Senator Poore
SYNOPSIS
This resolution designates May 5-11, 2024, as Tardive Dyskinesia Awareness Week and encourages anyone experiencing uncontrollable, abnormal, and repetitive movements to consult their healthcare provider regarding their symptoms.
Author: Senator Poore